Switch from IVIg to Hizentra for CIDP nerve inflammation
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests Hizentra® as an alternative to IV immunoglobulin (IVIg) for adults with CIDP, a condition where the immune system damages the nerves. You may be able to switch to Hizentra if your current IVIg treatment is keeping your CIDP stable and you can switch safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have CIDP diagnosed using the EAN/PNS 2021 criteria
- Plan to switch from IVIg to Hizentra®
- Have had at least 3 IVIg treatment courses and your doctor feels you depend on IVIg
- Have been stable for the past 3 months, meaning no changes to your CIDP treatment
- Have a smartphone, tablet, or computer and can follow study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.